Headlines

Eli Lilly (LLY) announces that from January 1st 2027, Zepbound, Mounjaro and Orforglipron will be available through Medicare Part D participating plans

Newsquawk Staff ·

  • On cmmi balance model for GLP-1s, patient's cost-sharing will be limited to USD 245/month plus dispensing fee before patients reach their deductible

What it means

Eli Lilly's announcement regarding Medicare Part D coverage for its key products suggests a significant market expansion for Zepbound, Mounjaro, and Orforglipron, improving affordability for patients. This move could enhance Eli Lilly's revenue growth prospects and boost sentiment toward pharmaceutical stocks, as it reflects strategic positioning in a competitive sector. Investors should monitor potential impacts on overall healthcare expenditure and competitors' responses in the market.

Related headlines